Shares of Agenus Inc. (NASDAQ:AGEN) rose 7.2% during trading on Thursday . The company traded as high as $4.05 and last traded at $4.02. Approximately 1,624,063 shares were traded during trading, an increase of 35% from the average daily volume of 1,206,246 shares. The stock had previously closed at $3.75.

AGEN has been the topic of a number of research analyst reports. BidaskClub cut Agenus from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 target price on shares of Agenus in a research report on Friday, August 4th. Zacks Investment Research cut Agenus from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Finally, ValuEngine upgraded Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Agenus currently has an average rating of “Hold” and a consensus target price of $5.81.

The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.37). The company had revenue of $3.40 million during the quarter, compared to analyst estimates of $5.91 million. The business’s revenue was down 24.4% on a year-over-year basis. research analysts predict that Agenus Inc. will post -1.19 EPS for the current fiscal year.

In related news, CEO Garo H. Armen purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 7.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in Agenus in the 3rd quarter valued at about $134,000. Highbridge Capital Management LLC increased its position in Agenus by 242.8% in the 3rd quarter. Highbridge Capital Management LLC now owns 56,642 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 40,118 shares during the period. Schwab Charles Investment Management Inc. increased its position in Agenus by 6.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 282,015 shares of the biotechnology company’s stock valued at $1,244,000 after acquiring an additional 16,470 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Agenus by 511.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 74,407 shares during the period. Finally, Artal Group S.A. increased its position in Agenus by 25.0% in the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after acquiring an additional 500,000 shares during the period. Hedge funds and other institutional investors own 39.52% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Agenus Inc. (AGEN) Stock Price Up 7.2%” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/agenus-inc-agen-stock-price-up-7-2/1722382.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.